GE Healthcare launched its hand-held ultrasound, Vscan Access, last May at a World Health Organization meeting in Switzerland. Now, the technology is in the process of becoming more widely available and incorporated into routine pregnancy care.
Expansion-minded CRO PSI has opened up shop in Israel, expanding its global reach to cover a market the company believes is poised for growth.
R&G; Pharma Studies, a Chinese CRO, is deepening its relationship with clinical trial tech provider Medidata, adopting the company's cloud-based management system.
By year-end, the United Arab Emirates (UAE) can expect to have a new manufacturing plant producing drugs for the country as a Saudi drugmaker completes the first phase of a project there.
Chinese CRO WuXi PharmaTech just went private in a $3.3 billion deal, but the company is looking to get back on the public markets through an IPO for its biologics business, according to Bloomberg.
GlaxoSmithKline is upping its presence in India again, saying this week that it'll spend INR500 million ($73 million) on a plant upgrade in Nashik to expand its thyroid and dermatology offerings.
Beijing, China-based contract research organization Pharmaron has snapped up fellow CRO Quotient Bioresearch as it looks to broaden its reach both technically and geographically.
Capsulemaker Qualicaps is adding another country, and another continent, to its manufacturing network. It has secured a spot in Brazil with the acquisition of a capsulemaker there.
Some drugmakers are expanding production in Africa to take advantage of a growing number of countries where rising incomes and national healthcare can pay for new meds. Now, through a number of sources of financing, a new plant will be built to manufacture yellow fever vaccine, a protection that has been in short supply.
Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.